This database contains 175 studies, archived under the term: "administration & dosage"
Click here to filter this large number of results.
The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer’s dementia: a prospective withdrawal and rechallenge pilot study
Padala, Kalpana P.,
Padala, Prasad R.,
McNeilly, Dennis P.,
Geske, Jenenne A.,
Sullivan, Dennis H.,
Potter, Jane F.
Background: Statins are well-known for their cardiovascular benefits. However, the cognitive effects of statins are not well understood. We hypothesized that individuals with preexisting dementia would be more vulnerable to statin-related cognitive effects.; Objective: The aim of this study was to evaluate the impact on cognition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (statin) discontinuation and rechallenge […]
Achetylcholinesterase (AChE) inhibition and serum lipokines in Alzheimer’s disease: friend or foe?
Kovacs, Janos,
Pákáski, Magdolna,
Juhasz, Anna,
Feher, Agnes,
Drótos, Gergely,
Fazekas, Csilla Orsike,
Horvath, Tamas Laszlo,
Janka, Zoltan,
Kálmán, János
Throughout the natural progression of Alzheimer’s disease (AD), the body mass index (BMI) decreases. This is believed to be brought on by the disturbance in the central lipid metabolism, but the exact mechanism is yet unknown. Adipokines (adiponectin, leptin), hormones produced by the adipose tissue, change glucose and lipid metabolism, and have an anorectic effect […]
Evaluation of the regional cerebral blood flow changes during long-term donepezil therapy in patients with Alzheimer’s disease using 3DSRT
Kimura, Noriyuki,
Kumamoto, Toshihide,
Masuda, Teruaki,
Hanaoka, Takuya,
Okazaki, Toshio,
Arakawa, Ryuki
Background: We attempt to evaluate objectively the regional cerebral blood flow (rCBF) changes during long-term donepezil therapy and the relationship between the clinical response and rCBF change in patients with Alzheimer’s disease (AD).; Patients and Methods: Thirty-one patients with mild-to-moderate AD (11 men, 20 female; mean age, 76.2 ± 6.7 years) were treated with donepezil […]
The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design
Devanand, D. P.,
Mintzer, Jacobo,
Schultz, Susan,
Sultzer, David,
de la Pena, Danilo,
Gupta, Sanjay,
Colon, Sylvia,
Schimming, Corbett,
Pelton, Gregory H.,
Andrews, Howard,
Levin, Bruce
Objectives: : Research studies on the effects of discontinuing antipsychotic medications in patients with dementia have not identified specific target symptoms or response to antipsychotics prior to discontinuation. The Antipsychotic Discontinuation in Alzheimer Disease (ADAD) trial addresses these issues in a randomized, double-blind, placebo-controlled, multicenter risperidone treatment and discontinuation trial. In Phase A, AD patients […]
A proteomics study reveals a predominant change in MaoB expression in platelets of healthy volunteers after high protein meat diet: relationship to the methylation cycle
Zellner, Maria,
Babeluk, Rita,
Jakobsen, Lene H.,
Gerner, Christopher,
Umlauf, Ellen,
Volf, Ivo,
Roth, Erich,
Kondrup, Jens
Studies investigating the impact of high meat intake on cognition have yielded contradictory results as some show improved cognitive performance, whereas others report an increase of risk factors for dementia. However, few studies were designed to directly assess the effect of a high protein (HP) diet on both cognitive performance and corresponding biochemical parameters. A […]
Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease – protocol for a controlled, randomized double-blinded trial
Egefjord, Lærke,
Gejl, Michael,
Møller, Arne,
Brændgaard, Hans,
Gottrup, Hanne,
Antropova, Olga,
Møller, Niels,
Poulsen, Henrik E.,
Gjedde, Albert,
Brock, Birgitte,
Rungby, Jørgen
Introduction: Type 2 diabetes (DM-2) increases the risk of developing Alzheimer´s disease (AD), and patients with AD are more likely to develop DM-2. DM-2 and AD share some pathophysiological features. In AD, amyloid-β (Aβ) is accumulated as extracellular plaques in the gray matter of the brain, while in DM-2 islet amyloid polypeptide (IAPP) is accumulated […]
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects
Dockens, Randy,
Wang, Jun-Sheng,
Castaneda, Lorna,
Sverdlov, Oleksandr,
Huang, Shu-Pang,
Slemmon, Randy,
Gu, Huidong,
Wong, Oi,
Li, Hewei,
Berman, Robert M.,
Smith, Christina,
Albright, Charles F.,
Tong, Gary
Background and Objectives: Avagacestat is an orally active γ-secretase inhibitor that selectively inhibits amyloid β (Aβ) synthesis in cell culture and animal models. The objective of the current study was to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of multiple doses of avagacestat over 28 days in healthy young men and elderly men and women […]